Press release from Companies
Publicerat: 2024-06-28 14:32:15
Q&A on German IPO, Structural Enhancements, and Growth Strategies.
Q&As from the CEO It may be a lengthy summary, but based on the questions and pitches we receive, it's essential to provide complete insight into our plans and intentions for business growth. 1. REFINED COMPANY STRUCTURE We've streamlined our group structure to enhance operational efficiency, meet new EU Medical Device Regulation requirements, and align with our strategic objectives. CS MEDICA oversees four key subsidiaries, each specializing in different aspects of our business. This structure ensures comprehensive control over the entire value chain while leveraging the strengths of each subsidiary. Strategic Intentions: The CS MEDICA Group: As a MedTech pioneer specializing in cannabinoid-based treatments for pain management, autoimmune, and stress-related disorders, we focus on delivering patient-centric self-care. Our products range from innovative R&D to registered over-the-counter substance-based medical devices and dermaceuticals. Our flagship CANNASEN® brand exemplifies our commitment to safe, high-quality treatments for both human and veterinary health globally. CS MEDICA A/S – Holding Company and Group Parent: The CS MEDICA Group structure ensures high quality, regulatory compliance, and optimal resource utilization, fostering growth and market expansion. Centralizing IP rights within CS MEDICA allows for strategic licensing opportunities, enhancing operational flexibility and long-term growth potential. 2. OPERATIONAL OPTIMIZATION The Letter of Intent (LOI) with GP Europe Holding B.V. marks the beginning of a transformative partnership. This collaboration represents vertical integration aligned with our strategic goal of controlling the entire value chain—from hemp cultivation and cannabis isolate production to product manufacturing and sales. Key Benefits: Next Steps: 3. FUNDING, SHAREHOLDER OPPORTUNITIES, AND STOCK SPIN-OFF DETAILS CS MEDICA Group can secure funding through share issuance in the parent company or an IPO in CANNORDIC a/s. This spin-off can reposition CS MEDICA by redefining CANNORDIC's equity story based on market insights and strategic reflections. Funding Opportunities: Shareholder Opportunities: Next Steps for CS MEDICA and Shareholders:
I want to reflect on our recent achievements and outline structural enhancements based on the EGM resolution. I'll detail how we aim to build resilience to secure future growth and increase shareholder value.
For more information about CS MEDICA, please contact:
Lone Henriksen, CEO
Phone: + (45) 71 20 30 47
Email: lh@cs-medica.com
Website: https://www.cs-medica.com/